Literature DB >> 33669657

Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer.

Ciara S McNevin1,2, Anne-Marie Baird3, Ray McDermott4,5, Stephen P Finn1,6.   

Abstract

Prostate Cancer (PCa) is a leading cause of morbidity and mortality among men worldwide. For most men with PCa, their disease will follow an indolent course. However, advanced PCa is associated with poor outcomes. There has been an advent of new therapeutic options with proven efficacy for advanced PCa in the last decade which has improved survival outcomes for men with this disease. Despite this, advanced PCa continues to be associated with a high rate of death. There is a lack of strong evidence guiding the timing and sequence of these novel treatment strategies. This paper focuses on a review of the strategies for diagnostic and the current evidence available for treatment selection in advanced PCa.

Entities:  

Keywords:  CRPC; castration-resistant prostate cancer; dynamic classification; mHSPC; metastatic hormone-sensitive prostate cancer; prostate cancer; systemic therapy; treatment strategies

Year:  2021        PMID: 33669657     DOI: 10.3390/diagnostics11020345

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  7 in total

1.  Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells.

Authors:  Mariana Morais; Vera Machado; Francisca Dias; Patrícia Figueiredo; Carlos Palmeira; Gabriela Martins; Rui Fernandes; Ana Rita Malheiro; Kirsi S Mikkonen; Ana Luísa Teixeira; Rui Medeiros
Journal:  Int J Nanomedicine       Date:  2022-09-16

2.  RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer.

Authors:  Hao Su; Yutao Wang; Hongjun Li
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

3.  Antitumor Activity and Mechanism of Action of Hormonotoxin, an LHRH Analog Conjugated to Dermaseptin-B2, a Multifunctional Antimicrobial Peptide.

Authors:  Mickael Couty; Marie Dusaud; Mickael Miro-Padovani; Liuhui Zhang; Patricia Zadigue; Loussiné Zargarian; Olivier Lequin; Alexandre de la Taille; Jean Delbe; Yamina Hamma-Kourbali; Mohamed Amiche
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

4.  Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.

Authors:  Guopeng Yu; Jiahao Bao; Ming Zhan; Jiangyi Wang; Xinjuan Li; Xin Gu; Shangqing Song; Qing Yang; Yushan Liu; Zhong Wang; Bin Xu
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

5.  Identification of characteristic metabolic panels for different stages of prostate cancer by 1H NMR-based metabolomics analysis.

Authors:  Xi Zhang; Binbin Xia; Hong Zheng; Jie Ning; Yinjie Zhu; Xiaoguang Shao; Binrui Liu; Baijun Dong; Hongchang Gao
Journal:  J Transl Med       Date:  2022-06-17       Impact factor: 8.440

6.  BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored.

Authors:  Felice Crocetto; Biagio Barone; Vincenzo Francesco Caputo; Matteo Fontana; Ottavio de Cobelli; Matteo Ferro
Journal:  Diagnostics (Basel)       Date:  2021-05-19

Review 7.  AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption.

Authors:  Navid Sobhani; Praveen Kumar Neeli; Alberto D'Angelo; Matteo Pittacolo; Marianna Sirico; Ilaria Camilla Galli; Giandomenico Roviello; Gabriella Nesi
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.